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Abstract 
Macrophages exhibit a phenotypic plasticity that enables them to orchestrate specific 
immune responses to distinct threats. However, the factors that control macrophage 
behaviour in a context dependent manner are not well understood.  Lipopolysaccharide 
(LPS) and the extracellular matrix glycoprotein tenascin-C both activate toll-like receptor 
4 (TLR4), and are released during bacterial infection and tissue injury, respectively.  
Here we report that these two TLR4 ligands induce distinct macrophage signalling 
pathways and phenotypes.  Macrophages activated by LPS or tenascin-C display some 
common features, including NF-kB and MAP kinase signalling, and cytokine synthesis.  
However, different subsets of cytokines, and different phosphoproteomic signatures, are 
produced by each stimulus.  Moreover, tenascin-C promotes macrophages more inclined 
to matrix synthesis and phosphorylation, whilst LPS-activated macrophages exhibit an 
elevated capacity to degrade matrix.  These data reveal how activation of one pattern 
recognition receptor by different microenvironmental cues, signalling pathogen invasion 
or tissue damage, can create unique macrophage phenotypes. 
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Introduction 
Macrophages are innate immune sentinels that patrol the majority of tissues in the body.  
These cells detect changes in the microenvironment including pathogen invasion and 
tissue damage, and in response mediate inflammatory processes that destroy microbial 
interlopers, remove and repair damaged tissue, and restore homeostasis 1. Macrophages 
are versatile cells that orchestrate both the induction and the resolution of inflammation. 
They can be driven towards a pro-inflammatory phenotype, or a tissue repair phenotype, 
by specific differentiation protocols in vitro.  However, a much larger spectrum of 
macrophage subsets exists in vivo, enabling a context dependent response to specific 
types and locations of threat 2.  The microenvironment of these cells is therefore key to 
defining their behaviour; both the surrounding cocktail of soluble cues (including 
cytokines, growth factors and microbial products) and the network of extracellular matrix 
molecules specific to the tissue location of the macrophage impact its function 3, 4.  
Accumulating evidence demonstrates how environmental factors, including heme 5, 
retinoic acid 6 and TGF-7 influence the specialization of tissue-resident macrophages.  
Moreover, transfer of tissue-resident macrophages to a different tissue has indicated that 
the microenvironment can reprogram fully differentiated macrophages 4.   
Macrophages are equipped with pattern-recognition receptors (PRRs), including Toll-like 
receptors (TLRs), NOD-like receptors, RIG-I family, lectins and scavenger receptors, 
which they use to sense changes in the microenvironment 8.  PRRs detect a wide variety 
of threats; and whilst receptor specificity exists, there is also a surprising amount of 
overlap in ligand recognition.  For example, TLRs recognize molecules produced by 
pathogens ranging from bacterial lipoproteins to viral nucleic acids, as well as 
endogenous molecules generated upon tissue damage, including self nucleic acids, 
phospholipids, small organic molecules, fatty acids and a variety of proteins and 
proteoglycans 9. This convergence of distinct microenvironmental signals on the same 
receptor family has raised the question of whether infection and sterile tissue injury are 
interpreted equivalently by the innate immune system; and whilst the mechanisms of 
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pathogen-mediated TLR activation, signalling and downstream inflammatory responses 
have been extensively investigated, those mediated by cues signalling sterile tissue 
damage remain enigmatic. 
We sought to undertake a systematic analysis of the signalling pathways and biological 
outcomes induced by two different stimuli, from infected and damaged 
microenvironments respectively, that activate the same PRR.  We directly compared two 
TLR4 activators: the Gram-negative bacterial lipopolysaccharide (LPS) and tenascin-C, 
an extracellular matrix glycoprotein specifically induced upon tissue injury 10.  Tenascin-
C activation of TLR4 induces cytokine synthesis in a wide variety of cells including 
macrophages and fibroblasts 11-13.  Although transiently induced upon tissue damage, 
tenascin-C is persistently expressed in chronic inflammatory diseases and in tumors 10.   
We previously demonstrated that the C-terminal fibrinogen-like globe (FBG) domain of 
tenascin-C is responsible for TLR4 activation, and that this domain is potently 
arthritogenic, driving persistent TLR4-mediated disease in models of inflammatory 
arthritis 11.  Here, we show that activation of TLR4 by LPS or FBG generates two distinct 
macrophage phenotypes, which display different activation markers, secrete different 
effector molecules and induce different phosphoproteomic profiles driving unique 
signalling pathways and protein interaction networks, and creating macrophages with 
distinct catabolic and anabolic abilities.  Collectively, our study provides evidence that 
the innate immune system can interpret the context of an inflammatory cue and 
orchestrate inflammation accordingly by instructing macrophage behaviour. 
 
Results 
LPS and the FBG domain of tenascin-C induce distinct macrophage activation 
phenotypes  
LPS recognition by TLR4 induces a well-defined macrophage phenotype 2. To determine 
whether FBG activation of TLR4 promotes a macrophage phenotype similar to that 
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induced by LPS, we compared a combination of markers in LPS- and FBG-treated 
macrophages. We used M-CSF-cultured macrophages from human peripheral-blood 
monocytes (M-CSF-MDMs), and examined macrophage markers known to be activated 
by LPS or by alternative stimuli such as IL-4 14.  Stimulation with either 1 ng/ml of LPS 
or 1 μM of the FBG domain of tenascin-C induced comparable IL-6 secretion and 
Arginase-1 (Arg1) mRNA expression (Fig 1A), whilst IL-23 and IL-12 secretion was 
induced only by LPS (Fig. 1B).  At these concentrations, FBG induced significantly more 
IL-8 (Fig. 1C) and significantly less TNF-α and IL-10 (Fig. 1D) compared to LPS.  Finally, 
1μM FBG sustained the expression of the mannose receptor, C type 1 (MRC1) compared 
to 1 ng/ml LPS, which turned off MRC1 mRNA synthesis by 24 hr (Fig. 1E). 
To rule out any contribution of contaminating LPS in FBG activated macrophages, FBG 
was pre-treated with polymyxin B, which neutralizes LPS-induced cytokine synthesis but 
not that induced by FBG (fig. S1A).  To ensure that differences in marker expression 
were not due to loss of viable cells upon stimulation, we assessed cytotoxicity by MTT 
assay and found that neither LPS nor FBG had any effect on cell viability (fig. S1B).  
Finally, to confirm that the analysed markers are directly induced in response to TLR4 
activation, we stimulated macrophages with FBG or LPS in the presence or absence of a 
TLR4 function blocking antibody or TAK-242, an inhibitor of TLR4 signal transduction.  
Both TLR4 inhibitors effectively abrogated LPS- and FBG-induced cytokine synthesis (Fig. 
1F shows data for TNF-, IL-6 and IL-10) and re-established basal MRC1 expression (Fig. 
1G). Together, these results indicate that macrophages recognize FBG and LPS through 
TLR4 and, in response, change their activation state toward the M(IL-4) and M(LPS) 
activation standards 14, respectively. 
LPS and the FBG domain of tenascin-C generate unique macrophage 
phosphoproteomic signatures 
To further examine differences in LPS- and FBG-activated macrophages we assessed 
protein phosphorylation, as a readout of signal transduction in response to cell 
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stimulation. Fluorescent two-dimensional difference gel electrophoresis (2D-DIGE) 
followed by mass spectrometry (MS) analysis was used to enable an unbiased and 
quantitative analysis of the global macrophage phosphoproteome 15 (Fig. 2A and B). 
Macrophages were stimulated with LPS or the FBG domain of tenascin-C, or were left 
unstimulated.  Immobilized metal ion-affinity chromatography (IMAC) was used to enrich 
phosphorylated proteins from macrophage lysates. Yields of enriched phosphoprotein 
were quantified (fig. S2A) and the efficiency of phosphoprotein enrichment verified (fig. 
S2B to D). Control, LPS- and FBG-treated phosphoproteins were each labelled with the 
fluorescent dye Cy3, and an internal standard, containing a mixture of equal amounts of 
each experimental protein sample, with Cy5.  Paired samples were separated by 2D-
PAGE. Gels were subjected to multi-wavelength fluorescent scanning, to identify spots 
with at least 1.5-fold changes (p ≤ 0.05) compared to the internal standard, and these 
spots were excised from a preparative gel for MS analysis.  68 phosphoproteins that 
were differentially regulated by stimulation with 1 ng/ml LPS or 1 M FBG compared to 
control cells were identified. LPS and FBG each differentially regulated 43 and 23 
phosphoproteins compared to control, respectively.  Only 2 phosphoproteins, dermcidin 
isoform 2 [DCD-2] and prelamin-A/C [LMNA Q5TCI8]), were identified as being regulated 
by both stimuli (Fig. 2C and D).  A number of proteins were selected for validation by 
immunoblotting phosphoprotein fractions from control, LPS- and FBG-stimulated cells. 
These data confirmed the changes revealed by 2D-DIGE for PSMA6, PSME1 DCD and 
COL1, plus -tubulin, which was included as a control that was not regulated by any 
stimulus (fig. S2E).  However, whilst immunoblotting confirmed the FBG-mediated 
induction of p38 (MAPK14) observed by 2D DIGE, it also showed that LPS induced p38 
phosphorylation (fig. S2E); this is a signaling event not identified in the proteomic 
screen but which we would expect based on what is known about LPS activation of TLR4.  
Together these data indicate that we can use the 2D-DIGE approach to reliably identify 
subsets of signalling molecules activated by macrophages in response to different 
stimuli, but do highlight that this technique will not yield an exhaustive list of activated 
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molecules.  These data also emphasize the importance of independent validation to 
confirm data from this type of analysis, particularly when using primary human cells. 
LPS- and FBG-induced phosphorylation drives divergent signalling pathways  
In order to obtain insight into the types of proteins and the biological pathways identified 
as being regulated by LPS or FBG stimulation of macrophages using 2D DIGE we 
performed a number of in silico analyses.  Gene Ontology (GO) analysis examines the 
cellular location of regulated phosphoproteins, their class identity based on function and 
cellular compartment, and the biological systems to which they contribute.  These data 
revealed that the majority of macrophage phosphoproteins regulated by stimulation with 
1ng/ml LPS are intracellular, as expected 16, while there was an over-representation of 
extracellular phosphoproteins enriched from cells treated with 1M FBG (fig. S3A). 
Chaperone, defence/immunity and calcium-binding proteins were amongst the most 
strongly populated classes from LPS-regulated phosphoproteins (fig. S3B). Accordingly, 
metabolic and immunological processes were well represented among LPS-regulated 
phosphoproteins (fig. S3C). These observations are in line with previous studies 
investigating LPS-regulated phosphorylation in macrophages 16, 17. FBG-stimulated cells 
had unique enriched protein classes, including extracellular matrix proteins, kinases, 
nucleic acid binding, receptor transporter and surfactant, and biological processes such 
as apoptosis, that were not seen with LPS (fig. S3B and C). However, LPS and FBG 
stimulation also led to the enrichment of many common biological processes (e.g. 
immune system processes, cellular processes and cellular component organization) and 
protein classes (e.g. defence/immunity protein, cytoskeletal protein, transcription factor, 
enzyme modulator, transfer/carrier protein and protease), indicating overlap in the 
biological outcomes following activation of macrophage TLR4 by each stimulus. 
Next, we used the STRING database of known and predicted protein interactions, to 
identify specific pathways targeted by the phosphorylation events induced by LPS or 
FBG, and to better understand the molecular organization and the relationships among 
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these phosphoproteins. In figure 3A and B we show the top 15 significantly enriched 
pathways downstream of LPS and FBG stimulation, respectively. We identified LPS 
activated pathways that would be expected based on published data; these include MAPK 
signalling pathway 16, 17, endocytosis 16, immune signalling pathways such as antigen 
processing and presentation 18 and complement 19 and coagulation 20 cascades, and 
infection-related pathways (e.g. influenza A and Epstein-Barr virus infection) which 
corroborate a role for TLR4 signalling in response to viral infection 21. We also found 
significant representation of signalling pathways that substantiate emerging observations 
linking TLR signalling with endoplasmic reticulum activity in macrophages 22, estrogen 
signalling 23, the spliceosome 24, thyroid hormone synthesis 25 and biosynthesis of amino 
acids 26 (Fig. 3A).  In contrast, distinct signalling pathways emerged from the analysis of 
FBG-stimulated cells. In agreement with published literature, we observed enrichment 
for platelet activation 27, ECM-receptor interaction 28, focal adhesion 28, 29, leukocyte 
migration 30, PI3K-Akt signalling 31, and VEGF signalling 32 pathways. However, we also 
found novel signalling pathways in immune defence, including amoebiasis, Epstein-Barr 
virus infection, NOD-like receptor signalling, shigellosis and epithelial cell signalling in 
Helicobacter pylori infection. Furthermore, this analysis identified for the first time the 
proteasome as a FBG activated pathway. 
Figures 3C and D show the protein-protein interaction networks composed of 
phosphoproteins upregulated by 1 ng/ml LPS and 1M FBG, respectively. Notably, 69% 
of LPS- induced and 73% of FBG-induced phosphoproteins are directly interconnected in 
the STRING network. This high degree of connectivity indicates that LPS and FBG 
regulate components of functional pathways or protein complexes rather than causing 
random protein phosphorylation events in macrophages. Interestingly, upon FBG 
stimulation of macrophages, this analysis predicted MAPK11 (p38) and MAPK14 (p38 
or p38 MAPK) to act as nodal kinases and collagen types I, II and III as nodal 
extracellular matrix molecules (Fig. 3D). 
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Together, these bioinformatic data highlight biological outcomes common to LPS and the 
FBG domain of tenascin-C, but also reveal differences in the macrophage response to 
these distinct microenvironmental stimuli. However, while GO, KEGG pathway and 
protein interaction network analyses help to explore experimental datasets and provide 
testable hypotheses, independent experimental validation is required to draw any 
conclusions. We chose two pathways to further investigate. Firstly, the MAPK signalling 
pathway given that FBG mediated phosphorylation of p38 kinases has not yet been 
investigated in macrophages; and, secondly, the phosphorylation of collagen molecules 
given that this was unique to FBG and has never been reported in macrophages or 
downstream of TLR4 activation.  
Both LPS and the FBG domain of tenascin-C induce p38 and JNK MAP kinases, 
and NF-kB signalling, upon TLR4 activation 
LPS-mediated TLR4 activation stimulates phosphorylation of the MAP kinases p38 and 
JNK and the activation of NF-kB regulated gene transcription.  Phosphorylation of 
p38and  emerged as a key event following FBG activation of macrophages (Fig. 4A 
and fig. S4A), however nothing is known about MAPK signalling downstream of this TLR4 
stimulus. 
Immunoblotting of phosphoprotein enriched and unphosphorylated protein fractions from 
FBG stimulated macrophages with a phospho-p38 (Thr180/Tyr182) antibody confirmed 
p38activation by FBG (see fig. S2E and S4B).  We next compared LPS and FBG  
induction of  p38 phosphorylation over time using macrophage donors independent of 
those used in the phosphoproteomic screen. Phospho-western blotting of macrophage 
lysates revealed that both FBG and LPS could induced p38 phosphorylation; that 
induced by 1M FBG appeared more transient having peaked by 30 minutes (min) in 
macrophages from all donors, whereas 1 ng/ml LPS on average sustained 
p38phosphorylation for longer (Fig. 4B).  FBG increased intracellular staining of 
phospho-p38 (fig S4C) and also induced the phosphorylation of MKK3 and MKK6, 
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specific upstream kinases, that are necessary for p38 activation (fig. S4D).  Stimulation 
of cells with FBG or LPS also induced JNK phosphorylation; here the magnitude of both 
JNK1 and JNK2/3 activation was higher in cells treated with 1 ng/ml LPS compared to 1 
M FBG (Fig. 4C).  In addition, 1 M FBG induced significant degradation of IkB- with a 
peak at 90 min that (30 min later than 1 ng/ml LPS) (Fig. 4D) and activated an NF-kB 
driven reporter gene overexpressed in monocytic cell lines to a similar extent and with 
similar kinetics compared to LPS (fig. S4E). FBG-induced MAPK and NF-kB activity was 
effectively inhibited by the TLR4 function blocking antibody (Fig. 4E to G and fig. S4F). 
These results demonstrate that, similarly to LPS, the FBG domain of tenascin-C triggers 
the p38 and JNK MAPK and NF-kB pathways through activation of TLR4. 
The FBG domain of tenascin-C induces macrophage collagen synthesis and 
phosphorylation 
Among the most abundantly upregulated phosphoproteins in FBG-activated macrophages 
were collagen type I (COL1A1 and COL1A2), II (COL2A1) and III (COL3A1); these 
molecules were not phosphorylated upon stimulation with 1 ng/ml LPS, nor in 
unstimulated macrophages (Fig. 2B and 3D).  We confirmed these data by subjecting 
phosphoprotein enriched fractions to immunoblot analysis with collagen type I antibody 
(fig. S2G).  Although collagen phosphorylation has been reported before 33-38(Cell 
Signaling Technology (CST) curation sets, www.PhosphoSitePlus.org) (Fig. 5A), the 
impact of collagen phosphorylation on its structure and function is not known, nor is the 
biosynthesis of these large fibrillar extracellular matrix molecules by macrophages well 
characterized.  
We examined if the expression of the collagens observed in our phosphoproteomic 
screen was regulated at the mRNA level after macrophage activation with 1 ng/ml LPS or 
1 M FBG.  COL1A1 and COL1A2 mRNA expression was similarly induced by both LPS 
and FBG. In contrast, COL2A1 mRNA was induced exclusively by FBG and not by LPS, 
while COL3A1 mRNA was not detected (Fig. 5B). This stimulus-specific collagen 
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production by macrophages is mediated through activation of TLR4, as the synthesis of 
COL1A1, COL1A2 and COL2A1 can be prevented by TAK-242, (Fig. 5C). We extended 
this analysis to examine the expression of each of the 28 types of collagen in 
macrophages upon LPS or FBG stimulation, comparing the abundance of each collagen in 
macrophages with primary human dermal fibroblasts (DFs), one of the most prolific 
cellular sources of collagen.  COL10A1, COL11A1, COL16A1 and COL26A1 were detected 
only in DFs, but not in macrophages; COL20A1 and COL22A1 were detected neither in 
macrophages nor in DFs. With the exception of COL17A1, which was equally expressed 
in DFs and macrophages, and COL23A1, which was more abundantly expressed in 
macrophages than in DFs, macrophages expressed lower levels of collagen molecules 
compared to DFs, as expected (Fig. 5D and fig. S5E). COL4A2, COL6A1, COL9A1, 
COL13A1, COL17A1, COL18A1, COL25A1 and COL27A1 were regulated to a similar 
extent by both LPS and FBG in macrophages. Notably, compared to LPS, FBG was a 
stronger inducer of COL8A1, which is upregulated upon injury 39, and COL23A1 and 
COL24A1, which are found in cancer 40, 41; conditions in which tenascin-C plays an 
established role 42. In contrast to FBG, LPS induced higher expression of Fibril Associated 
Collagens with Interrupted Triple helices (FACIT), namely COL7A1, COL12A1, COL15A1, 
COL19A1 and COL21A1, as well as the collagenase-resistant COL5A1 and the collagen 
containing von Willebrand factor COL28A1 (Fig. 5D and fig. S5F). Collectively, these data 
show that macrophages can significantly contribute to collagen synthesis and that 
pathogenic stimuli drive the synthesis of FACIT collagens that maintain the integrity of 
the extracellular matrix, while matrix-derived cues instruct macrophages to synthesize 
COL2A1 and phosphorylate collagens. 
LPS, but not FBG, stimulates the synthesis of macrophage collagenases 
To determine whether the degradation, as well as the synthesis, of collagen by 
macrophages is differentially affected by the FBG domain of tenascin-C and LPS, we 
investigated key matrix metalloproteinases (MMPs), including MMP1 or interstitial 
collagenase, MMP13 or collagenase 3 and MMP14, a type-I transmembrane MMP that 
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breaks down collagen, gelatin and other matrix molecules. MMP1 expression was 
significantly and rapidly upregulated by 1 ng/ml LPS, while 1 M FBG induced a modest 
increase at later time points.  At these concentrations FBG did not induce MMP13 
synthesis in contrast to LPS, which promptly and transiently upregulated its expression.  
Furthermore, MMP14 synthesis was induced 24 hours after cell stimulation with FBG, but 
not with LPS (Fig. 6A).  This stimulus-specific MMP profile is mediated through activation 
of TLR4, as the synthesis of each enzyme was completely abrogated by TAK-242 (Fig. 
6B).  
MMP activity is highly regulated at several levels. To determine whether the distinct 
expression of MMPs induced by the two TLR4 ligands is translated to function, we tested 
the collagenolytic and gelatinolytic activity of LPS- and FBG-activated macrophages. LPS-
activated macrophages efficiently degraded collagen, an activity that was reversed by 
the broad-spectrum MMP inhibitor GM6001, while FBG-activated cells showed little 
collagenolytic activity (Fig. 6C). These results are in line with collagenase expression 
profiles for each stimulus (MMP1 mRNA and protein in Fig. 6A and fig. S6 and MMP13 
mRNA in Fig. 6A). Macrophages constitutively degraded gelatin and continued to do so 
upon stimulation with FBG. Conversely, LPS-activated macrophages were unable to 
degrade gelatin (Fig. 6D upper three panels). The macrophage gelatinolytic activity did 
not match MMP14 mRNA levels (Fig. 6A), but did correlate with MMP14 protein surface 
expression, which was low to undetectable in LPS-activated macrophages and largely 
unaltered in FBG-activated cells (Fig. 6D lower panel), suggesting some degree of post-
transcriptional regulation of MMP14 activity. Together, these data indicate that LPS, but 
not the FBG domain of tenascin-C, licences macrophages to degrade collagen but 
prevents them from degrading gelatin, affecting their substrate specificity.  
Discussion 
Detection of both pathogen invasion and sterile tissue damage by the same PRRs has 
been recognized for over a decade.  However, the specificity of the inflammatory 
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outcomes downstream of infection and injury remains poorly understood.  This study 
directly compared the molecular signatures induced in primary human macrophages via 
activation of the same TLR by distinct microenvironmental stimuli.  We show that the 
pro-inflammatory, extracellular matrix glycoprotein tenascin-C and microbial LPS 
activated a common set of signalling pathways, including NF-kB and MAPK, but that 
these stimuli also induced different signalling pathways downstream of TLR4.  Although 
both stimuli induced cytokine synthesis, they generated different cytokine programmes.  
Moreover, the FBG domain of tenascin-C promoted a macrophage phenotype more 
inclined to matrix molecule synthesis and phosphorylation, whilst LPS promoted a 
macrophage with an elevated capacity to degrade matrix.  Together these data illustrate 
how endogenous and exogenous activation of TLR4 can create different macrophage 
phenotypes (Fig. 7). 
Using a combination of markers, we found two distinct activation phenotypes for 
macrophages that were exposed to 1M of the FBG domain of tenascin-C or to 1ng/ml 
LPS. These data indicate that tenascin-C can shift the macrophage activation phenotype 
towards the IL-4 activation standard; it was unable to induce IL12 or IL23, and induced 
less TNF- than LPS, but sustained MRC1 expression, whilst IL-6 and Arg1, which are 
expressed throughout the whole spectrum of activated macrophages, were equally 
induced by both stimuli 14. However, whilst there is some overlap in phenotype, 
tenascin-C can generate a type of macrophage that, in contrast to the IL-4 activation 
standard, induces less IL-10 than LPS, making it rather different to an archetypal 
[M(IL4)]. These data exemplify the diverse nature of macrophage subsets, revealing how 
the microenvironment is key to fine tuning their phenotype.   
By combining phosphoprotein enrichment with 2D-DIGE and MS analysis, we captured a 
snapshot of tenascin-C- and LPS-induced changes in the macrophage phosphoproteome 
that reflects the first 30 min of receptor activation. We also employed multiple 
bioinformatics tools to explore the experimental data set. Although there are a few 
phosphoproteomic reports targeted toward different TLRs in response to pathogenic 
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ligands 16, 17, this is the first study comparing the phosphoprotein signatures of 
exogenous and endogenous ligands of a specific TLR.  Overall, this analysis revealed two 
distinct yet overlapping phosphoproteomes.  In line with this, immunoblot validation 
analysis confirmed that, while tenascin-C but not LPS induced PSMA6 phosphorylation 
and PSME1 dephosphorylation, both tenascin-C and LPS induced DCD phosphorylation.  
Bioinformatics analysis identified the majority of LPS-induced phosphoproteins as 
intracellular and those induced by tenascin-C as extracellular. The latter comprised 
several extracellular matrix molecules, including COL1 which we validated by 
immunoblot, suggesting a role for tenascin-C-mediated activation of TLR4 in changing 
the macrophage microenvironment.  Along these lines, the KEGG pathway analysis and 
the protein interaction networks highlighted differences and similarities among LPS- and 
tenascin-C-regulated phosphoproteins. On the one hand, tenascin-C displayed 
enrichment of pathways that underlines an interplay between the cells and the 
microenvironment, including extracellular matrix-receptor interactions, focal adhesion 
and leukocyte migration. In line with this, strong connectivity between matrix molecules 
emerged from the tenascin-C-regulated phosphoprotein interaction network. On the 
other hand, an overlap in terms of innate/infection related pathways induced by both 
stimuli emerged. 
As with other TLR phosphoproteomic studies 16, 17, 36, our study did not identify all of the 
phosphoproteins that belong to the TLR pathway, indicating that the screen does not 
completely recapitulate the complex effect of TLR activation in macrophages. 
Observational proteomic data sets are by nature incomplete, either because of limited 
coverage of the regulated phosphoproteome or the possibility that not all pathway 
components are regulated by phosphorylation or have already been dephosphorylated or 
degraded at the time point chosen. However, strengthening the validity of our 
experimental data is 1) the identification of several phosphoproteins classically linked to 
the TLR pathway, including NF-kB (i.e. NF-kappa-B essential modulator (IKBKG) 43 and 
clusterin (CLU) 44) and MAPK (i.e. MAPK14 and MAPK11); 2) the phosphorylation of 
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cytoskeletal and actin binding proteins (e.g. plastin-2 (LCP1) 45, septin-2 (SEPT2), 11 
(SEPT11) 46 and vimentin (VIM) 47), essential for macrophage motility and phagocytosis, 
as reported before for LPS 16, 17; 3) the identification of pathways known to be linked to 
tenascin-C function (e.g. VEGF signalling 48 and focal adhesion 29); 4) the finding of 
phosphoproteins that have recently been implicated in TLR activity (e.g. Annexin A1 
(ANXA1), A2 (ANXA2) 49, 50 and SWAP70 51) or have implicated a function for TLRs in 
glycolysis 52 (alpha-enolase (ENO1) and GAPDH); 5) the identification of kinases known 
to be activated upon TLR4 activation (e.g. phosphatidylinositol-5-phosphate 4-kinase 
type-2 alpha (PIP4K2A) 53-55 and eukaryotic elongation factor 2 kinase (EEF2) 56); and 6) 
the enrichment of endogenous danger signals whose expression is induced upon TLR4 
activation and can themselves activate TLR4 if released 57 (e.g. S100A8, fibrinogen 
(FGB) and several heat shock proteins (HSP90AB1, HSPA8, HSPA5, HSPA1L and 
HSPA1A). 
Independent validation experiments of tenascin-C-regulated phosphoproteins and 
targeted phospho-westerns confirmed activation of p38 MAPK and revealed activation 
of the JNK MAPK and NF-kB, all pathways shared by LPS. Moreover, mass spectrometry 
analysis revealed that in addition to Thr180 and Tyr182 known to be phosphorylated in 
p38 by LPS, a new phosphorylation site at Ser272 was induced by FBG. This may be FBG 
specific and could account, at least in part, for the differences in FBG and LPS induced 
signalling. However, we could not validate phosphorylation of Ser272 as a phospho-
specific antibody for this site is not available.   
We found that stimulation of macrophages with 1 M tenascin-C, but not 1 ng/ml LPS, 
results in phosphorylated collagen enrichment. These data suggest that tenascin-C 
activates the synthesis, and posttranslational modification of other matrix molecules by 
macrophages, and places production of phosphorylated collagen molecules downstream 
of macrophage TLR signalling.  Phosphorylation of extracellular matrix molecules, 
including collagen type I and secreted pro 1(I) N-propeptide, by casein kinases was 
first reported more than 40 years ago 58, 59. More recently phosphorylation of collagen 
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XVII has been shown to negatively regulate its shedding by TACE 34, and 
phosphorylation of other extracellular molecules has been implicated in the regulation of 
cell adhesion and susceptibility to proteolytic cleavage. Notably, the ability of tenascin-C 
to regulate the phosphorylation of non-kinase proteins has been reported. It promotes 
PDGFR- autophosphorylation thereby enhancing its crosstalk signalling with v3 
integrin and, in turn, promoting proliferation and migration of smooth muscle cells 60.  
 
Hemocytes, the phagocytes of invertebrates, have been recently shown to synthesize 
collagen type IV in the germline stem cell niche in Drosophila 61. In humans, a handful of 
studies have reported the synthesis of collagen molecules in macrophages and have 
suggested that these proteins may play a role in anchoring macrophages to the 
extracellular matrix and stabilize atherosclerotic plaques in vivo 62-64. One study looked 
at collagen  mRNA synthesis by monocytes and macrophages, however only reported 
whether expression was detected or not without providing any quantitative data  64. We 
therefore screened for the expression of all 28 collagen molecules, including those found 
by the proteomic study, in LPS- or tenascin-C-activated and non-activated macrophages 
and compared it to that of human dermal fibroblasts, which are established matrix 
factories. With the exception of collagen type XXIII, whose expression was higher in 
macrophages, the abundance of 21 of the 22 collagen molecules detected in 
macrophages is higher in fibroblasts as expected. However, the most interesting finding 
regards collagen type II, which can be significantly induced by 1 M of tenascin-C, but 
not by 1 ng/ml LPS, through activation of TLR4. This indicates that matrix-derived, but 
not pathogenic microenvironmental cues can instruct macrophages to synthesize 
collagen type II and reveals a novel phenotypic signature of macrophages activated by 
distinct stimuli which operate through the same receptor. This change of the cellular 
microenvironment may affect the macrophage interaction with the surrounding 
extracellular matrix given that this collagen molecule interacts with integrin receptors 
and proteoglycans 65, 66. The induction of collagen type II by tenascin-C in macrophages 
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may be relevant in diseases such as rheumatoid arthritis where, on the one hand, 
tenascin-C expression is elevated and sustains inflammation via TLR4 11 and, on the 
other hand, antibodies to native and citrullinated collagen type II are produced 67.  
In the tissue, it is possible that the production and modification of collagen by tenascin-
C-activated macrophages counterbalances macrophage production of degradative 
enzymes.   This is supported by our findings that, upon activation of TLR4 by 1 ng/ml 
LPS, macrophages produce more MMP1 compared to those activated by 1 M of the FBG 
domain of tenascin-C, and that, at these concentrations, only LPS activated 
macrophages can express MMP13 and degrade collagen in vitro. Thus, while tenascin-C 
enables macrophages to shape the biochemistry of the matrix, LPS licences 
macrophages to degrade it.  
A number of questions remain to be answered, foremost of which is why distinct gene 
expression profiles are generated by a matrix-derived microenvironmental cue and a 
pathogenic component, given that both activate NF-kB and MAPK through TLR4. The 
answer may lie in the recruitment of distinct adaptor molecules early in the cascade. This 
may be regulated by receptor dimerization, which is essential for signalling by 
pathogenic components, but may not be the case for endogenous molecules. 
Alternatively, this may be explained by the distinct co-receptor and accessory molecule 
requirements for pathogenic and endogenous ligands in order to activate TLR4. For 
instance, LPS requires MD-2 and CD14, while tenascin-C does not 11 and hyaluronan 
fragments use MD-2 and CD44 but not CD14 and generate distinct patterns of gene 
expression compared to LPS 68.    
Another key question remains around how the FBG domain activates macrophage TLR4 
in vivo; what are the physiologically relevant concentrations, and form(s), of this region 
of tenascin-C?  It should be noted that this study assessed the response of macrophages 
to a single, different dose of LPS and of the FBG domain of tenascin-C, at a single time 
point; as such we can only make conclusions about how cells respond under these 
restricted conditions.  It is also difficult to know how the concentrations of the stimuli 
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that we examined correspond to what a macrophage will actually encounter in vivo.  
Whilst tissue concentrations of tenascin-C have been reported in the range of 0.37 – 1.2 
μM 69, 70, levels are likely dependent on the tissue location and circumstance.  Moreover, 
here we have focused on a direct comparison of LPS- versus FBG-mediated TLR4 
signaling.  It may be that during tissue injury tenascin-C is degraded releasing 
proteolytic fragments comprising the FBG domain that are free to activate TLR4 in 
isolation from the rest of the tenascin-C molecule.  Indeed, FBG containing tenascin-C 
fragments have been found in gingival crevicular fluid from a subset of periodontitis 
patients71.  Alternatively, macrophages could encounter intact tenascin-C that may either 
be soluble or incorporated into the tissue matrix.  We previously showed that full-length 
tenascin-C induces TLR4-mediated cytokine synthesis equally as well as the FBG domain 
alone11.  However, going forward it will be important to examine not only how the FBG 
domain signals when present with other domains of tenascin-C that together may 
synergistically affect macrophage activation, but also within the context of an insoluble 
3D multicomponent extracellular matrix. 
In conclusion, our data demonstrate that specific stimuli induce overlapping yet distinct 
biological outcomes upon activation of the same innate immune receptor. This study 
provides evidence that the innate immune system can interpret qualitatively different 
challenges and instruct inflammatory responses accordingly. It also highlights that not 
only the microenvironment affects TLR function, but also TLR activation affects the 
microenvironment. Understanding how the cellular microenvironment regulates 
macrophage phenotype and behaviour may help address how to manipulate 
inflammation to tissue injury and infection.  
 
Materials and methods 
Cell culture and stimulation. Primary human monocytes isolated from peripheral 
blood (London Blood Bank, London, UK) were differentiated into M-CSF-monocyte-
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derived macrophages (M-CSF-MDMs) by culturing them in RPMI 1640 containing 5% 
(v/v) FBS (GIBCO), 100 U/ml penicillin/streptomycin (PAA) and 100 ng/ml recombinant 
human M-CSF (Peprotech) for 5 days72. Adherent cells were washed, re-plated in RPMI 
1640 containing 3% (v/v) FBS (GIBCO) and 100 U/ml penicillin/streptomycin (PAA) for 
24 hours before stimulation with 1 ng/ml LPS (LPS from E. coli, serotype EH100(Ra), 
TLR-grade; Enzo Life Sciences) or 1 M FBG for 5, 15, 30 min or 1, 2, 3, 4, 8 and 24 
hours. Recombinant human FBG was synthesized and purified as previously described11 
and, where stated, was pre-incubated with 10 g/ml polymyxin B (Sigma).  
Inhibitors. MDMs were stimulated for 30 min or 1, 1.5, 2 and 24 hours with FBG or LPS 
in the presence or absence of DMSO, TAK-242 (3 M; Invivogen), PAb-h TLR4 (1, 10 or 
25 g/ml; Invivogen), isotype control (Rat PAb Control; 1, 10 or 25 g/ml; Invivogen), 
or GM6001 (10 M).  
Phosphoprotein enrichment and CyDye labelling. MDMs (8 x 106) were treated 
either with medium alone or with medium containing 1 M FBG or 1 ng/ml LPS for 30 
min before performing immobilized metal ion affinity chromatography (IMAC)73 using the 
PhosphoProtein Purification Kit (Qiagen). 5 g of phosphoprotein-enriched fractions were 
labelled with 6 nM Cy3 and an internal standard (IS), containing a mixture of equal 
amounts of each experimental protein sample, was labelled with 6 nM Cy5 saturation 
fluorescent dye according to the manufacturer’s instructions (CyDye DIGE Fluor Labeling 
Kit for Scarce Samples, GE Healthcare) by the proteomic services at the Cambridge 
Centre for Proteomics (www.bio.cam.ac.uk/proteomics). Briefly, labelling was optimized 
by titrating the reducing agent Tris-(2-carboxyethyl) phosphine hydrochloride (TCEP) 
and Cy3 and Cy5 dye. TCEP:dye molar ratio was kept 1:2 (1.5 nM TCEP and 3 nM dye; 2 
nM TCEP and 4 nM dye; 2.5 nM TCEP and 5 nM dye; 3 nM TCEP and 6 nM dye; and 4 nM 
TCEP and 8 nM dye). The IS was included on each gel within the experiment. Proteins 
were reduced with 3 nM TCEP for 1 hour at 37ºC in the dark and labelled with 6 nM Cy3 
or Cy5 for 30 min at 37ºC in the dark. The labelling reaction was quenched using 2 x 
sample buffer (7 M urea, 2 M thiourea, 4% CHAPS) containing 2% Pharmalytes and 130 
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mM DTT. Rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS, 1% Pharmalyte, broad 
range pH 3-10NL, 13 mM DTT) was added prior to isoelectric focusing (IEF) of labelled 
phosphoproteins.  
Two-dimensional difference gel electrophoresis (2D-DIGE). 2D-DIGE was 
performed by the proteomic services at the Cambridge Centre for Proteomics 
(www.bio.cam.ac.uk/proteomics) as previously described 15. Briefly, nonlinear 
immobilized pH gradient (IPG) strips (13 cm long), pH 3-10NL (GE Healthcare) were 
rehydrated with CyDye-labelled samples for 10 hours at 20ºC at 20 V using the IPGphor 
II apparatus (GE Healthcare) following manufacturer’s instructions. IEF was performed 
for a total of 40,000 Vh at 20ºC at 50 mA. Prior to SDS-PAGE, the strips were 
equilibrated for 15 min in 100 mM Tris pH 8.8, 30% glycerol, 6 M urea, 2% SDS, 0.2 
mg/mL, 0.5% (w/v) DTT on a rocking table. The strips were loaded onto a 12%, pH 8.5, 
13 cm (1mm thick) acrylamide gel with a 1 cm 4%, pH 6.8, stacker gel. The strips were 
overlaid with 1% agarose in SDS running buffer containing 5 mg of bromophenol blue. 
The gels were run at 20 mA for 15 min and then at 40 mA at 20ºC until the bromophenol 
blue dye front had run off the bottom of the gels. A 10x Tris/Glycine/SDS running buffer 
(BIO-RAD) was used. A total of 13 gels were run, including 12 analytical gels (10 g 
phosphoproteins/gel) representing 4 biological replicates and 1 preparative gel (170 g 
of combined phosphoproteins in total).  
Gel imaging and statistical analysis. After 2D-DIGE, Cy-Dye-labelled proteins were 
visualized using a Typhoon™ 9400 Imager (GE Healthcare), generating overlaid, multi-
channel images for each gel. The Cy3 images were scanned using a 532 nm laser and a 
580 nm band pass (BP) 30 emission filter. Cy5 images were scanned using a 633 nm 
laser and a 670 nm BP30 emission filter. To ensure maximum pixel intensity for the two 
dyes (between 40,000 and 60,000 pixels), all gels were scanned at 100 m pixel 
resolution and the photo-multiplier tube (PMT) voltage was set between 500-700 V. 
The scanned gel images were then transferred to the ImageQuant V5.2 software 
package (GE Healthcare). After cropping, the images were exported to the DeCyder 
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Batch Processor and BVA (Biological Variation Analysis) Module (DeCyder™ 2D Software 
V5.2; GE Healthcare) for statistical analysis, following manufacturer’s recommendations. 
To compare protein spots across gels, a master image was picked from images of 
internal standard. The statistical analysis of protein level changes between different cell 
stimulations was performed by the DeCyder-BVA (Biological Variation Analysis V5.2) 
module. Landmark spots were manually defined to improve the automated matching 
results. The preparative gel was scanned and matched with the master gel in order to 
assign the right correspondence for spot picking. Data were normalized for computing 
the fold changes. Protein spots with a statistically significant variation (p ≤ 0.05), 
showing a difference in volume of 1.5 fold compared to non-stimulated samples, were 
selected as differentially expressed and analysed by mass spectrometry.  
Protein identification by mass spectrometry. The preparative gel was silver stained 
for spot excision. The silver-stained image was scanned and spot matched to fluorescent 
images to ensure accurate excision of proteins of interest. Gel spots were excised from 
the gels using a 10mL pipette tip and were placed into a 96 well PCR plate. The gel spots 
were destained, reduced (DTT) and alkylated (iodoacetamide) and subjected to 
enzymatic digestion with sequencing grade trypsin (PROMEGA) overnight at 37°C. After 
digestion, the supernatant was pipetted into a sample vial and loaded onto an 
autosampler for automated LC-MS/MS analysis. 
All LC-MS/MS experiments were performed using a nanoAcquity UPLC (Waters 
Corporation) system and an LTQ Orbitrap Velos hybrid ion trap mass spectrometer 
(Thermo Scientific). Separation of peptides was performed by reverse-phase 
chromatography using a Waters reverse-phase nano column (BEH C18, 75 m i.d. x 250 
mm, 1.7 m particle size) at flow rate of 300 nL/min. Peptides were initially loaded onto 
a pre-column (Waters UPLC Trap Symmetry C18, 180 m i.d x 20mm, 5 m particle size) 
from the nanoAcquity sample manager with 0.1% formic acid for 3 min at a flow rate of 
10 L/min. After this period, the column valve was switched to allow the elution of 
peptides from the pre-column onto the analytical column. Solvent A was water + 0.1% 
22 
 
formic acid and solvent B was acetonitrile + 0.1% formic acid. The linear gradient 
employed was 5-40% B in 60 min. 
The LC eluant was sprayed into the mass spectrometer by means of a New Objective 
nanospray source. All m/z values of eluting ions were measured in the Orbitrap Velos 
mass analyzer, set at a resolution of 30000. Data dependent scans (Top 20) were 
employed to automatically isolate and generate fragment ions by collision-induced 
dissociation in the linear ion trap, resulting in the generation of MS/MS spectra. Ions with 
charge states of 2+ and above were selected for fragmentation.  Post-run, the data was 
processed using Protein Discoverer (V1.2, ThermoFisher).  Briefly, all MS/MS data were 
converted to mgf files and these were submitted to the Mascot search algorithm (Matrix 
Science, London UK) and searched against the UniProt Human database, using a fixed 
modification of carbamidomethyl (C), a variable modification of oxidation (M) and in 
specific cases, phosphorylation (Y,S,T) using a peptide tolerance of 20 ppm (MS) and 
0.1Da (MS/MS). Peptide identifications were accepted if they could be established at 
greater than 95.0% probability. 
Bioinformatic analysis. Gene ontology (GO) annotation enrichment analysis was 
performed using PANTHER V8.1 classification system (http://www.pantherdb.org/)74. 
The background data set for the analysis was the Homo sapiens genome and the 
binomial test (p < 0.05) was used for statistical overrepresentation. KEGG pathway 
enrichment and interaction network analyses were performed using STRING V10.0 
(http://string-db.org/)75. The background data set for the analyses was the Homo 
sapiens genome. Experimentally observed protein phosphorylation data mining was 
conducted using PhosphoSitePlus (http://www.phosphosite.org/homeAction.do)76. 
Hierarchical clustering was performed using MultiExperiment Viewer v4.9 
(http://www.tm4/org/). 
Phospho-western blotting. 5 x 105 MDMs were stimulated and cell extracts were 
prepared in 60 l of lysis buffer (1% NP-40, 150 mM NaCl, 20 mM Tris, pH 7.5) 
containing 10 mM EDTA, 10 mM EGTA, 1 mM Na3VO4, 5 mM NaF and a protease inhibitor 
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cocktail. Extracts were separated on 10% SDS-PAGE gels and proteins transferred to 
nitrocellulose membrane. Membranes were blocked in 5% BSA in Tris-buffered saline 
containing 0.1% tween 20 (TBST) and sequentially probed with antibodies recognizing 
human phospho-JNK (p46/54; #9521), human phospho-p38 (#9211), human p38 
(#8690) (Cell Signaling Technology) and human IkB- (C-15), human -tubulin (B-7) 
and human actin (I-19) (Santa Cruz Biotechnology). Blots were stripped of antibody 
between analyses using ReBlot Plus Strong antibody stripping solution (Merck Millipore) 
and blocked again in 5% BSA-TBST. Densitometric analysis of bands was carried out 
using Phoretix 1D software (TotalLab) and results are presented as relative band 
volumes.  
ELISA. Cell supernatants were examined by ELISA for the presence of TNF-, IL-6 and 
IL-8 (R&D Systems), IL-10 and IL-12 (BD Biosciences) and IL-23 (eBioscience) 
according to the manufacturer’s instructions. Absorbance was read on a 
spectrophotometric ELISA plate reader and analysed using the Ascient software (Thermo 
Labsystems). 
RNA extraction, Quantitative Real-Time PCR and RT-PCR. Total RNA was extracted 
from MDMs (1.5 x 106) using a RNeasy Mini Kit (QIAGEN). cDNA was synthesized from 
equivalent amounts of RNA with the High Capacity cDNA Reverse Transcription Kit using 
random primers (Applied Biosystems). Quantitative real-time PCR was performed in a 
ViiA 7 machine (Applied Biosystems) with TaqMan primer sets for human COL1A1 
(Hs00164004_m1), COL1A2 (Hs00164099_m1), COL2A1 (Hs00264051_m1), COL3A1 
(Hs00943809_m1), COL4A2 (Hs01098873_m1), COL5A1 (Hs00609133_m1), COL6A1 
(Hs01095585_m1), COL7A1 (Hs00164310_m1), COL8A1 (Hs00156669_m1), COL9A1 
(Hs00932129_m1), COL10A1 (Hs00166657_m1), COL11A1 (Hs01097664_m1), 
COL12A1 (Hs00189184_m1), COL13A1 (Hs01103879_m1), COL14A1 
(Hs00964045_m1), COL15A1 (Hs01557124_m1), COL16A1 (Hs00156876_m1), 
COL17A1 (Hs00990036_m1), COL18A1 (Hs00181017_m1), COL19A1 
(Hs00156940_m1), COL20A1 (Hs00612130_m1), COL21A1 (Hs00229402_m1), 
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COL22A1 (Hs01377192_m1), COL23A1 (Hs00297526_m1), COL24A1 
(Hs00537698_m1), COL25A1 (Hs00261300_m1), COL26A1 (Hs00294957_m1), 
COL27A1 (Hs00259829_m1), COL28A1 (Hs00417144_m1), MMP1 (Hs00899658_m1), 
MMP13 (Hs00233992_m1), MMP14 (Hs00237119_m1), MRC1 (Hs00267207_m1), Arg1 
(Hs00968979_m1) and HPRT1 (Hs02800695_m1). Changes in expression were 
calculated by the change-in-threshold (ΔΔCT) method with HPRT1 as endogenous control 
for gene expression and were normalized to results obtained with non-stimulated cells. 
Collagen film degradation assay.  A collagen film degradation assay was carried out 
as described previously 77. Briefly, MDMs were seeded on six-well culture plates coated 
with a thin layer of fibrillar type I bovine collagen (3 mg/ml; PureCol) in the presence or 
absence of LPS or FBG, with and without GM6001. 5 days later, cells were removed by 
trypsinization and plates were fixed with 3% paraformaldehyde in TBS for 20 min and 
stained with Coomassie Brilliant Blue R250. Images were captured with a charge-coupled 
device camera-equipped microscope (Nikon TE2000-E). Degraded areas were visualized 
as white, unstained, non-collagen-containing zones.  
Fluorescently labelled gelatin (F-gelatin) film degradation assay. A gelatin film 
degradation assay was carried out as described previously 77. Briefly, glass coverslips 
(18 mm in diameter) were coated with Alexa Fluor 488-conjugated gelatin. MDMs were 
seeded onto F-gelatin-coated coverslips in the presence or absence of LPS, FBG and/or 
GM6001 and cultured for 64 hours. After, cells were fixed with 3% paraformaldehyde in 
TBS for 15 min and immunostained. Cells were incubated with blocking solution (5% 
(v/v) goat serum, 3% (w/v) BSA in TBS) for 1 hour at room temperature followed by 
incubation with rabbit anti-human MMP14 (ab51074, Abcam) diluted in blocking solution 
for 2 hours at room temperature. After washing 4xTBS, cells were incubated with Alexa 
Fluor 568-conjugated secondary anti-rabbit IgG (Molecular Probes, Eugene) diluted in 
blocking solution for 1 hour at room temperature and nuclei were stained with DAPI. 
After washing 4xTBS, cells were mounted onto glass slides using ProLong Gold Antifade 
Reagent (Invitrogen). Controls that were stained in the absence of primary antibody 
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were included. Images were captured with a charge-coupled device camera-equipped 
microscope (Nikon TE2000-E). Degraded areas were visualized as dark, non-fluorescence 
zones. 
Statistical analysis. Statistical analysis was performed using paired t test, one-way 
ANOVA or two-way ANOVA with Sidak’s multiple comparisons test where appropriate 
(Prism 6; GraphPad software). 
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Figure legends 
Figure 1. Activation of M-SCF-MDMs upon stimulation of TLR4 with LPS or the 
FBG domain of tenascin-C 
(A) ELISA of IL-6 secreted by M-CSF-MDMs stimulated for 1, 1.5, 2 and 24 hours with 
1ng/ml LPS or 1M FBG (pre-incubated with polymyxin B). Data are from nine 
independent experiments each with a different donor (mean ± SEM). Quantitative RT-
PCR analysis of Arg1 mRNA in M-CSF-MDMs stimulated for 8 and 24 hours with 1ng/ml 
LPS or 1M FBG (pre-incubated with polymyxin B). Results are presented relative to 
those of non-stimulated M-CSF-MDMs (n=4 independent experiments each with a 
different donor; mean ± SEM).  ns, not significant;one-way ANOVA. (B-D) ELISA of IL-
23 and IL-12 (B), IL-8 (C) and TNF- and IL-10 (D) secreted by M-CSF-MDMs stimulated 
for 4, 8 and 24 hours or 1, 1.5, 2 and 24 hours with 1ng/ml LPS or 1M FBG (pre-
incubated with polymyxin B). Data are from five to nine independent experiments each 
with a different donor (mean ± SEM). *p<0.05, **p<0.01, ****p<0.0001 and ns, not 
significant; one-way ANOVA. (E) Quantitative RT-PCR analysis of MRC1 mRNA in M-CSF-
MDMs stimulated for 1.5, 4, 8 and 24 hours with 1ng/ml LPS or 1M FBG (pre-incubated 
with polymyxin B). Results are presented relative to those of non-stimulated M-CSF-
MDMs (n=4 independent experiments each with a different donor; mean ± SEM). 
*p<0.05; one-way ANOVA. (F) ELISA of TNF-, IL-6 and IL-10 secreted by M-CSF-MDMs 
stimulated for 1, 1.5, 2 and 24 hours or 24 hours with 1ng/ml LPS or 1M FBG (pre-
incubated with polymyxin B) in the presence or absence of 25 g/ml polyclonal antibody 
specific for human TLR4 (PAb-h TLR4) or isotype control (left panel) and 3M TAK-242 or 
DMSO (right panel). Data are from three to five (left panel) and three to four (right 
panel) independent experiments each with a different donor (mean ± SEM). *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001; two-way ANOVA. (G) Quantitative RT-PCR 
analysis of MRC1 mRNA in M-CSF-MDMs stimulated for 24 hours with 1ng/ml LPS or 1M 
FBG (pre-incubated with polymyxin B) in the presence or absence of 3M TAK-242 or 
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DMSO. Results are presented relative to those of non-stimulated M-CSF-MDMs (n=3 
independent experiments each with a different donor; mean ± SEM). 
 
Figure 2. Phosphoproteomic profiling of M-CSF-MDMs upon LPS or FBG 
stimulation  
(A) Workflow of phosphoprotein enrichment and analysis in human M-CSF-MDMs by 
IMAC and 2D-DIGE. Cells were either left unstimulated or stimulated with 1ng/ml LPS or 
1M of the FBG domain of tenascin-C for 30 min and cell lysates were subjected to IMAC 
to enrich phosphoproteins (n=4 different donors for each condition: non-stimulated, 
LPS-stimulated and FBG-stimulated cells ). Phosphoprotein enriched fractions from 
individual samples and the internal standard (IS; a pool of equal amounts of each 
biological replicate) were labelled with CyDye DIGE Fluor Cy3 (green) and Cy5 (red) 
saturation dyes respectively, followed by 2D-DIGE. 2D analytical gels were loaded with 
5g of Cy3-labelled individual sample and 5g of Cy5-labelled IS. From each gel, two 
scan images were generated at different wavelengths and overlaid. Differentially 
expressed protein spots were identified and quantified using DeCyder 2D Differential 
Analysis software (p<0.05 determined by Student’s T-test; average ratio ≥1.5). 
Representative 2D analytical gels (pH 3-10) from one donor are shown. (B) Workflow of 
protein identification from 2D DIGE by MS analysis. A preparative gel was loaded with 
120g of total phosphoproteins (10g of each phosphoprotein enriched fraction prepared 
from cell lysates of M-CSF-MDMs from four independent donors that were not stimulated 
or stimulated with 1ng/ml LPS or 1M FBG for 30 min) and silver stained (left panel). 
This was matched to the analytical gel set using DeCyder 2D software to identify the 
differentially expressed protein spots that were determined by 2D DIGE analysis. The 
right panel shows the differentially expressed spots that were selected for automated 
spot-picking prior to protein digestion, followed by nLC-MS/MS analysis and Mascot 
database searching. (C) Phosphoproteins differentially regulated by LPS or FBG 
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stimulation of M-CSF-MDMs for 30min. The histogram shows up- and down-regulation as 
an average ratio (this is the normalized ratio between LPS-stimulated cells : 
unstimulated cells and between FBG-stimulated cells : unstimulated cells; n=4 
independent donors per group). Phosphoproteins are shown with gene names. Data are 
from one experiment (four biological replicates). (D) Venn diagram displaying 
phosphoproteins shared and specific to LPS- and FBG-stimulated M-CSF-MDMs and 
histogram showing numbers of phosphoproteins whose abundance was significantly 
increased or decreased by LPS or FBG. Data are from one experiment (four biological 
replicates).  
 
Figure 3. Regulated pathways and protein networks in LPS- versus FBG-
stimulated M-CSF-MDMs 
(A and B) Pathway analysis of phosphoproteins whose abundance was significantly 
increased by stimulation of M-CSF-MDMs with LPS (A) or the FBG domain of tenascin-C 
(B) for 30 min. Pie charts show the top 15 significantly enriched KEGG pathways 
(p<0.05) among the regulated phosphoproteins after LPS or FBG stimulation compared 
to non-stimulation. For each KEGG pathway, the pie chart sector shows the percentage 
of gene hit against total number of pathway hits. KEGG pathway enrichment was 
performed using STRING and the background data set for the analysis was the Homo 
sapiens genome. (C and D) Interaction networks of phosphoproteins whode abundance 
was significantly increased by stimulation of M-CSF-MDMs with LPS (C) or FBG (D) for 30 
min. The networks were constructed using STRING. Nodes (circles) represent 
phosphoproteins regulated by LPS (C) and FBG (D) and are labelled with gene names. 
Both connected and disconnected nodes are shown. Nodes were clustered and coloured 
using the Markov Cluster (MCL) algorithm according to their distance matrix. Edges 
(lines) indicate known and predicted protein-protein interactions and are drown with 
differently coloured lines according to the type of evidence; neighbourhood (green), co-
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occurrence (dark blue), experimental (purple), textmining (olive green), database 
(blue), homology (light blue) and co-expression (black). Ovals highlight proteins 
belonging to enriched KEGG pathways that are investigated in this study. Proteins in (i) 
belong to platelet activation, leukocyte transendothelial migration, Epstein-Barr virus 
infection, proteoglycans in cancer, amyotrophic lateral sclerosis, NOD-like receptor 
signaling, shigellosis, VEGF signaling, and epithelial cell signaling in Helicobacter pylori 
infection. Proteins in (ii) belong to platelet activation, amoebiasis, protein digestion and 
absorption, ECM-receptor interaction, focal adhesion, and PI3K-Akt signaling.    
 
Figure 4. The FBG domain of tenascin-C and LPS induce p38 and JNK MAPK and 
NF-kB signalling via TLR4 
(A) Schematic representation of MAPK11 (p38) and MAPK14 (p38). Protein kinase 
domain is shown in green and N- and C-terminal regions flanking the protein kinase 
domain in orange. Peptide sequences that were found by MS analysis are shown in grey. 
Starred, black letters indicate published phosphorylation sites and underlined, red letters 
indicate phosphorylation sites identified in this study (S272). (B-D) Immunoblot analysis 
of phospho-p38 (P-p38) (B), phospho-JNK1 (P-JNK1) and phospho-JNK2/3 (P-JNK2/3) 
(C), IkB-(D) and -tubulin (B-D) in cell lysates obtained from M-CSF-MDMs 0, 5, 15, 
30, 60, 90, 120 and 180 min after stimulation with 1M FBG or 1ng/ml LPS. Results are 
representative of four independent experiments each with a different donor. Histograms 
show quantification of P-p38 (B), P-JNK1 and P-JNK2/3 (C) and IkB- (D) normalized to 
levels of -tubulin by densitometric analysis (n=4; mean ± SEM). *p<0.05 and 
**p<0.01 compared to 0 min; one-way ANOVA. (E-G)  Immunoblot analysis of P-p38 
and p38 (E), P-JNK2/3 and P-JNK1 (F), Ik-(G) and -tubulin (F-G) in cell lysates 
obtained from M-CSF-MDMs 30 min (E), 1 hour (F) and 1 and 1.5 hours (G) after 
stimulation with 1M FBG (pre-incubated with polymyxin B) or 1ng/ml LPS in the 
presence or absence of 1, 10 or 25 g/ml (E) or 25 g/ml PAb-h TLR4 (F and G). Results 
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are representative of three to four independent experiments each with a different donor. 
Histograms show quantification of P-p38 (E), P-JNK1 (F) and IkB- (G) normalized to 
levels of p38 (E) and -tubulin (F and G) by densitometric analysis. Data are shown as 
percent activation relative to cells stimulated in absence of PAb-h TLR4 (n=3-4 
independent experiments each with a different donor; mean ± SEM). *p<0.05, 
**p<0.01 and ns, not significant; one-way ANOVA. 
 
Figure 5. Analysis of the collagen network in FBG- and LPS-activated M-CSF-
MDMs 
(A) Schematic representation of COL1A1, COL1A2, COL2A1 and COL3A1. Signal peptide 
sequences are shown in green, N- and C-terminal propeptide sequences in blue and 
collagen chain sequences in purple. Peptide sequences that were found by MS analysis 
are shown in grey. Letters indicate unpublished phosphorylation sites experimentally 
observed by Cell Signaling Technology (CST) and starred letters indicate published 
phosphorylation sites. (B) Quantitative RT-PCR analysis of COL1A1, COL1A2 and COL2A1 
mRNA in M-CSF-MDMs stimulated with 1M of the FBG domain of tenascin-C (pre-
incubated with polymyxin B) or 1ng/ml LPS for 1.5, 4, 8 and 24 hours. Results are 
presented relative to those of non-stimulated cells (n=3-5 independent experiments 
each with a different donor; mean ± SEM). *p<0.05, **p<0.01, ***p<0.001 and 
p****<0.0001; two-way ANOVA. (C) Quantitative RT-PCR analysis of COL1A1, COL1A2 
and COL2A1 mRNA in M-CSF-MDMs stimulated with 1M FBG (pre-incubated with 
polymyxin B) or 1ng/ml LPS for 8 (COL1A1 and COL1A2) or 24 hour (COL2A1) in the 
presence or absence of 3M TAK-242 or DMSO control. Data are presented as percent 
mRNA induction relative to cells stimulated in the absence of TAK-242 or DMSO (n=4-5 
independent experiments each with a different donor; mean ± SEM). *p<0.05, 
**p<0.01 and ns, not significant; one-way ANOVA comparing stimulated cells to non-
stimulated cells. (D) Quantitative RT-PCR analysis of collagen 1-28 in M-CSF-MDMs 
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stimulated with 1M FBG (pre-incubated with polymyxin B) or 1ng/ml LPS for 1.5, 4, 8 
and 24 hours. The heatmap shows suppression (green) and induction (magenta) of 
expression as fold change on a log2 scale, relative to non-stimulated cells. Connecting 
lines represent hierarchical clustering of the patterns of variation in expression of 
collagen genes (n=3 independent experiments each with a different donor). 
 
Figure 6. MMP expression and matrix degradation by FBG- and LPS-activated M-
CSF-MDMs 
(A) Quantitative RT-PCR analysis of MMP1, MMP13 and MMP14 in M-CSF-MDMs 
stimulated with 1ng/ml LPS or 1M of the FBG domain of tenascin-C (pre-incubated with 
polymyxin B) for 1.5, 4, 8 and 24 hours. Results are presented relative to those of non-
stimulated cells (n=4-5 independent experiments each with a different donor; mean ± 
SEM). *p<0.05, ***p<0.001 and ns, not significant; one-way ANOVA. (B) Quantitative 
RT-PCR analysis of MMP1, MMP13 and MMP14 mRNA in M-CSF-MDMs stimulated with 
1ng/ml LPS or 1M FBG (pre-incubated with polymyxin B) for 4 (MMP13) and 24 hours 
(MMP1 and MMP14) in the presence or absence of 3M TAK-242 or DMSO control. Data 
are presented as percent mRNA induction relative to cells stimulated with LPS or FBG in 
absence of TAK-242 (n=3-4 independent experiments each with a different donor; mean 
± SEM). ****p<0.0001; one-way ANOVA. (C) Collagen film degradation by M-CSF-
MDMs stimulated with or without (-) 1ng/ml LPS or 1M FBG (pre-incubated with 
polymyxin B) in the presence or absence of 10M GM6001 for 5 days. Digested areas of 
collagen are shown as white regions against grey collagen background. Images are 
representative of three independent experiments each with cells from a different donor. 
(D) Fluorescent gelatin film degradation by M-CSF-MDMs stimulated with or without (-) 
1ng/ml LPS or 1M FBG (pre-incubated with polymyxin B) in the presence or absence of 
10M GM6001 for 64 hours. Digested areas of gelatin are shown as black regions against 
green gelatin background. Cell surface MMP14 and DAPI immunofluorescence staining 
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are shown in red and blue, respectively. Images are representative of three independent 
experiments each with cells from a different donor.  
 
Figure 7. Model of the environmental influence on TLR4-mediated innate 
immune responses in macrophages 
TLR4 is exposed to and activated by distinct microenvironments, including infected as 
well as sterile, but damaged tissues. Both stimuli equally lead to activation of the NF-kB 
and MAPK signalling pathways and secretion of IL-6. However, while infection induces 
high levels of pro-inflammatory cytokines and tissue degrading enzymes, tissue damage 
promotes matrix molecule synthesis and posttranslational modification in addition to 
contributing to cytokine synthesis. Molecules induced exclusively by pathogens or tissue 
damage are shown in blue or red, respectively; those induced by both stimuli are shown 
in grey; P indicates phosphorylation.  
 
 
 
 
 
 
